AGMB
AgomAb Therapeutics N.V. American Depositary Shares NASDAQ$11.19
Mkt Cap $405.5M
52w Low $9.00
25.9% of range
52w High $17.45
50d MA $12.64
200d MA $12.99
P/E (TTM)
-8.9x
EV/EBITDA
0.0x
P/B
—
Debt/Equity
0.0x
ROE
—
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
0.00
50d MA
$12.64
200d MA
$12.99
Avg Volume
222.5K
About
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosi…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | AMC | -0.52 | -0.56 | -9.1% | 10.70 | -1.1% | +3.3% | +5.8% | -0.6% | +0.4% | +1.4% | — | — |
Data updated apr 26, 2026 9:28am
· Source: massive.com